Development of a Palatable Glycopyrronium Bromide Liquid for Paediatrics
Overview
The aim of the development program was to develop an aqueous, multidose oral liquid formulation of glycopyrronium bromide 2mg/5ml for the symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in paediatric patients aged 3 years and older with chronic neurological disorders.
Download our poster resource entitled, 'Development of a Palatable Glycopyrronium Bromide Liquid for Pediatrics.'